JPMorgan and Morgan Stanley enhance buybacks and dividends, even though Citigroup and BofA get more compact techniques

JPMorgan and Morgan Stanley enhance buybacks and dividends, even though Citigroup and BofA get more compact techniques


Important Points
  • JPMorgan claimed it was increasing its quarterly dividend 8.7% to $1.25 for every share and that it approved a new $30 billion share repurchase plan.
  • Morgan Stanley mentioned it was boosting its dividend 8.8% to 92.5 cents per share and authorized a $20 billion repurchase system.
  • Citigroup said it was boosting its dividend 5.7% to 56 cents per share and that it would “keep on to assess share repurchases” on a quarterly foundation.
  • Financial institution of America explained it was escalating its dividend 8% to 26 cents for every share its launch made no mention of share repurchases.



Source

These underperforming groups may deliver AI-electric appeal. Here’s why.
Finance

These underperforming groups may deliver AI-electric appeal. Here’s why.

ETF Edge These underperforming groups may deliver AI-electric appeal. Here’s why. Published Sat, Nov 15 202511:00 AM EST Blair Bao WATCH LIVE Source

Read More
Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet
Finance

Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet

Warren Buffett speaks during the Berkshire Hathaway Annual Shareholders Meeting in Omaha, Nebraska on May 3, 2025. CNBC Warren Buffett’s Berkshire Hathaway revealed a new position in Alphabet, making the Google parent the conglomerate’s 10th largest equity holding at the end of September, according to a regulatory filing. Berkshire disclosed a $4.3 billion stake in […]

Read More
Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more
Finance

Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more

Check out the companies making the biggest moves midday: Scholar Rock — The Cambridge, Massachusetts-based biotech jumped 23% after saying it ” completed constructive and collaborative in-person Type A meeting ” with the FDA on Wednesday for a biologics license application for apitegromab, a spinal muscular atrophy treatment. Officials from Novo Nordisk’s Catalent Indiana joined […]

Read More